Search

Displaying results 3311 - 3320 of 4233 in total
  1. Drug

    Cetyl ethylhexanoate

    go.drugbank.com/drugs/DB11349
    Investigational

    It is present in cosmetic products as a skin conditioning agent and emollient.

  2. Drug

    Emactuzumab

    go.drugbank.com/drugs/DB14905
    Investigational

    Emactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).

  3. Drug

    Acrizanib

    go.drugbank.com/drugs/DB16081
    Investigational

    Acrizanib is under investigation in clinical trial NCT02355028 (LHA510 Proof-of-concept Study as a Maintenance Therapy for Patients With Wet Age-related Macular Degeneration).

  4. Drug

    Sotevtamab

    go.drugbank.com/drugs/DB19120
    Investigational

    Sotevtamab is under investigation in clinical trial NCT06225843 (Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis).

    Synonyms: -chain) (human-mus musculus monoclonal ab-16b5 .gamma.2-chain), disulfide with human-mus musculus monoclonal ab-16b5 .kappa.-chain, dimer
  5. Drug

    Tick-borne encephalitis vaccine (whole virus, inactivated)

    go.drugbank.com/drugs/DB16611
    ApprovedInvestigational

    [A237520] TICOVAC (also known as TicoVac or FSME-IMMUN) was the first approved vaccine against TBE in Europe, first approved in 1976.

  6. Drug

    COVID19 s-vax loaded autologous dendritic cell vaccine

    go.drugbank.com/drugs/DB15814
    Experimental

    These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine. … As of May 2020, the company is pursuing a human clinical trial (ChiCTR2000033003) to test the safety and immunogenicity of the vaccine.

  7. Drug

    Strontium malonate

    go.drugbank.com/drugs/DB05732
    Investigational

    Strontium malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. It is being developed by Osteologix Inc.

  8. Drug

    mRNA-3351

    go.drugbank.com/drugs/DB17718
    Experimental

    Developed by Moderna, it is currently being investigated as the treatment for Crigler-Najjar syndrome

  9. Drug

    Sipuleucel-T

    go.drugbank.com/drugs/DB06688
    ApprovedInvestigational

    Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers.

  10. Drug

    Antihemophilic factor (recombinant), PEGylated

    go.drugbank.com/drugs/DB09329
    ApprovedInvestigational

    Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label].